Pharma

AbbVie’s new myeloma drug, etentamig, shows promise with a better side effect profile compared to competitors like J&J, Pfizer, and Regeneron. This development could have implications for American pharma industry competitiveness and potentially impact the future of myeloma treatment.

Pfizer has granted Medicus Pharma co-development rights to ADC PF-08046031, signaling a positive step in pharmaceutical collaboration. Meanwhile, Novartis’ decision to consolidate its biologics labs in Basel may impact around 130 jobs by 2027, highlighting the evolving landscape of the pharmaceutical industry.

Gossamer Bio has secured a private placement agreement worth up to $250 million, with $150 million committed to advancing the development and potential FDA approval of seralutinib. This funding announcement could have implications for American pharmaceutical innovation and the future availability of new treatments in the industry.

Gossamer Bio has announced a private placement agreement worth up to $250 million, with $150 million committed to advancing the development and potential FDA approval of seralutinib. This funding boost could have positive implications for American industry and pharmaceutical innovation.

Genentech has shared details about their new $2 billion manufacturing facility in North Carolina, which will feature advanced biomanufacturing, automation, and robotics. This development highlights ongoing investments in cutting-edge technology within the American pharmaceutical industry, showcasing advancements in production and manufacturing processes.

Bristol Myers has secured FDA approval for Zenbexus, a groundbreaking protein-degrading drug for multiple myeloma. This milestone marks the first of a new group of medicines that could revitalize Bristol Myers’ key drug franchise, potentially impacting American pharmaceutical industry and workers.

Moderna’s mFlusiva mRNA flu shot has been approved by the FDA, making it the first mRNA-based vaccine for flu prevention in the US market. While awaiting CDC recommendations, this development could have implications for American industry and healthcare workers involved in flu prevention efforts.

Resilience and Lilly have committed $750 million to enhance the production of Lilly’s KwikPen, aiming to bolster the supply of diabetes and obesity medications in the United States. This investment reflects a strategic move to strengthen American pharmaceutical manufacturing and meet the growing demand for essential medicines domestically.

BeOne Medicines is planning to invest $300 million in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey. This investment highlights a commitment to American industry and production, potentially benefiting workers and supporting the local economy.

Eli Lilly intends to file for regulatory approval of its investigational anti-obesity drug Retatrutide in early 2027 after successful late-stage trial results, targeting obesity and related conditions.